Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TC, de Jong-van den Berg LTDramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 60: 641-647

Groningen University Institute for Drug Exploration, University of Groningen, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands.
British Journal of Clinical Pharmacology (Impact Factor: 3.88). 01/2006; 60(6):641-7. DOI: 10.1111/j.1365-2125.2005.02502.x
Source: PubMed


To estimate the diffusion of new safety information concerning postmenopausal hormonal replacement therapy (HRT) into prescribing practice in The Netherlands and to assess the impact of revised guidelines on the long-term treatment of HRT.
Cross-sectional study.
Community pharmacy dispensing data from a population of approximately 450,000 patients in the northern and eastern part of The Netherlands.
Women aged 45-69 years to whom at least one HRT prescription was dispensed between 1 January 2000 and 1 January 2004.
Annual and quarter prevalences of HRT and the proportion of new HRT users, switchers and continuous HRT users per quarter.
The prevalence of HRT prescribing decreased significantly from 107/1000 [95% confidence interval (CI) 104, 110] in 2000 to 87/1000 (95% CI 84, 89) in 2003. The decreasing prevalence was especially evident among the younger age groups and was most pronounced among users of oestrogen/progestagen combinations. The publication of the Women Health Initiative Study (WHI) was followed by a modest decrease in prescribing of HRT, whereas prescribing of HRT declined dramatically after publication of the Million Women Study (MWS) in August 2003. Among the continuous HRT users in the 4th quarter of 2002, 55% used HRT longer than 3 years. This percentage was 53 in the 4th quarter of 2003.
In contrast to the release of the WHI study results, publication of the MWS was followed by a dramatic fall in prescribing of HRT in The Netherlands. Despite the new recommendation that long-term HRT use should be discouraged, the proportion of long-term users did not change after the publication of the MWS.

Download full-text


Available from: Toine Egberts
  • Source
    • "In epidemiological studies, progesterone levels during a first pregnancy at an early age are thought to confer protective effects against future breast tumor development [71,72]. However, the possible deleterious effect of certain progestins used in hormone replacement therapies (HRTs) after menopause and as contraceptives to counteract the proliferative action of unopposed estrogens on the uterus recently resurfaced in the Women’s Health Initiative and the Million Women studies [73,74]. These studies showed that a combined estrogen plus progestin regimen as HRT is associated with a greater risk of breast cancer than estrogen alone or placebo. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Progesterone is essential for the proliferation and differentiation of mammary gland epithelium. Studies of breast cancer cells have demonstrated a biphasic progesterone response consisting of an initial proliferative burst followed by sustained growth arrest. However, the transcriptional factors acting with the progesterone receptor (PR) to mediate the effects of progesterone on mammary cell growth and differentiation remain to be determined. Recently, it was demonstrated that signal transducer and activator of transcription 6 (Stat6) is a cell growth suppressor. Similar to progesterone-bound PR, Stat6 acts by inducing the expression of the G1 cyclin-dependent kinase inhibitors p21 and p27. The possible interaction between Stat6 and progesterone pathways in mammary cells was therefore investigated in the present study. ChIP and luciferase were assayed to determine whether Stat6 induces p21 and p27 expression by recruitment at the proximal Sp1-binding sites of the gene promoters. Immunoprecipitation and Western blotting were performed to investigate the interaction between Stat6 and PR-B. The cellular DNA content and cell cycle distribution in breast cancer cells were analyzed by FACS. We found that Stat6 interacts with progesterone-activated PR in T47D cells. Stat6 synergizes with progesterone-bound PR to transactivate the p21 and p27 gene promoters at the proximal Sp1-binding sites. Moreover, Stat6 overexpression and knockdown, respectively, increased or prevented the induction of p21 and p27 gene expression by progesterone. Stat6 knockdown also abolished the inhibitory effects of progesterone on pRB phosphorylation, G1/S cell cycle progression, and cell proliferation. In addition, knockdown of Stat6 expression prevented the induction of breast cell differentiation markers, previously identified as progesterone target genes. Finally, Stat6 gene expression levels increased following progesterone treatment, indicating a positive auto-regulatory loop between PR and Stat6. Taken together, these data identify Stat6 as a coactivator of PR mediating the growth-inhibitory and differentiation effects of progesterone on breast cancer cells.
    Full-text · Article · Jan 2014 · BMC Cancer
  • Source
    • "The Minnesota Heart Survey found a dramatic decline in HRT among women with an intact uterus within the first 6 months following the preliminary WHI results whereas few women who underwent hysterectomy discontinued therapy [13]. Following WHI, the 2003 Million Women Study (MWS) results also had a large impact on the prescribing of HRT in The Netherlands, with a decrease from 107 per 1000 women in 2000 to 87 in 2003 [14]. In Ireland , the prevalence of HRT fell from 19.3% in 2002 to 16.0% in 2003 following WHI, and to 12.3% in 2004, after MWS [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To survey the life prevalence and determinants of hormone replacement therapy (HRT) in Portugal. We evaluated 908 women with mean age (standard deviation) 62.3 (9.6) years, as part of the assembling of a cohort of adults, representative of Porto inhabitants. Extensive data collection was conducted and included socio-demographic, lifestyle and clinical characterisation. The latter comprised gynecologic and obstetric history, as well as lifetime use and duration of HRT. Life prevalence of hormone replacement therapy was 26.8% (95% confidence interval: 23.9-29.8). Prevalence of lifetime HRT was higher in younger (born after 1949: 37.1%) and more educated women (over 12 schooling years: 48.7%), as in white-collar workers (36.8%), and women using private healthcare (39.4%). HRT use was also more frequent among ever smokers (43.1%), and in women reporting regular sports practice (35.6%). Ever users of oral contraceptives underwent HRT more frequently (33.3%) and women who experienced menopause more recently were more likely to use HRT (after 1994: 40.5%). No differences were found in the prevalence of HRT according to whether women had been hysterectomised or oophorectomised. Education, regular sports practice and menopause year were independent determinants of HRT. Median duration of therapy was 2 years. Short-term HRT users were more educated, and had more recent menopause. Long-term HRT users were more educated, engaged in sports more frequently, and were more frequently oophorectomised. Prevalence of hormone replacement therapy increased until 2001 and was mainly determined by high socioeconomic status, regardless of important therapeutic indications, such as oophorectomy and hysterectomy.
    Full-text · Article · Aug 2007 · Maturitas
  • Source
    • "Using the SEER incidence data, we first calculated cumulative CRC incidence within the following 10 years among men and women for each single year of age between ages 50 and 75. The cumulative incidence within a given age range approximates the expected risk of developing a disease within the defined age interval in the absence of competing causes of death, assuming that age specific incidence rates remain constant over time (Day, 1987). Starting from the levels of 10-year cumulative incidence among men at ages 50, 55, and 60 (the most commonly implemented ages for initiation of CRC screening in existing programmes), we determined at what ages the same levels of 10-year cumulative incidence were observed among women. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is some variation regarding age at initiation of screening for colorectal cancer (CRC) between countries, but the same age of initiation is generally recommended for women and men within countries, despite important gender differences in the epidemiology of CRC. We have explored whether, and to what extent, these differences would be relevant regarding age at initiation of CRC screening. Using population-based cancer registry data from the US and national mortality statistics from different countries, we looked at cumulative 10-year incidence and mortality of CRC reached among men at ages 50, 55, and 60, and found that women mainly reached equivalent levels when 4 to 8 years older. The gender differences were remarkably constant across populations and over time. These patterns suggest that gender differentiation of age at initiation may be worthwhile to utilise CRC-screening resources more efficiently.
    Full-text · Article · Apr 2007 · British Journal of Cancer
Show more